Autoinjector CDMO: What a Device Partner Owes Your Program Beyond the Factory
Published 2026-10-30 · Keywords: autoinjector CDMO
Most autoinjector sourcing projects are decided on six criteria, scored before the first supplier call: freedom to operate, quality system, regulatory support, manufacturing capacity, cost and lead time, and track record. Price is only one input inside the fifth criterion — a supplier who cannot pass the first three will never be audited, no matter what the quotation says.
An autoinjector CDMO engagement buys more than manufacturing capacity — it buys a program partner who carries design controls, documentation and scale-up alongside your drug clock. The honest version of this article separates what a device CDMO actually provides from what stays with the sponsor, so your team can scope the engagement without buying services you already own.
What a device-side CDMO/CMO provides — and what it never does
| Workstream | Device CDMO provides | Stays with the sponsor |
|---|---|---|
| Platform selection | Configuration mapping against your dose table | Therapy and label decisions |
| Design controls | Design history file inputs, change control on the device | Combination-product strategy |
| Manufacturing | Validated batches, sterilization management, release testing | Drug substance and fill-finish |
| Documentation | ISO 11608 reports, ISO 10993-1 data, certificate pack | Submission ownership, agency interactions |
| Scale-up | Batch phasing, capacity planning, second-source optioning | Commercial volume commitments |
The dividing line is stable across serious suppliers: the CDMO owns the device workstream and its evidence; the sponsor owns the drug, the submission and the market decisions. A supplier who blurs that line in the sales conversation will blur it in the audit.
Where CDMO pricing differs from OEM pricing
OEM platform pricing is unit-price-led; CDMO engagement pricing is workstream-led — you are buying engineering and documentation hours plus capacity, priced as program phases (development, validation, launch, scale-up). The practical consequence: comparing a CDMO quotation to an OEM quotation on unit price alone compares two different purchases. Decide first which engagement you need — see OEM, ODM or CDMO — then compare like with like.
The three questions that reveal a real CDMO
- “Walk me through your last design-change control — what moved, who signed, what re-verification ran?” Real partners answer with a process; factories answer with a promise.
- “What documentation arrives at each phase gate?” Real answers name documents: updated spec sheets, re-verification reports, change assessments.
- “What do you NOT do?” A CDMO that states its boundary — no drug handling, no submission ownership, no clinical work — is structuring an engagement that survives audits. One that claims everything is pricing everything into your quote.
What this does not cover
Selection of your fill-finish partner, drug CDMO scoping and submission strategy are separate workstreams. This article covers the device-side engagement only.
Next step: send your program phase (pre-IND, pivotal, launch) and container format — we return the engagement scope our side can carry, with the boundary stated, within one working day. Start the inquiry.
Related reading
Talk to NOVIXPEN about your program
Send your container format, annual volume and target market — we reply with the platform match, documentation set and written quotation within one working day.
Start the inquiry